Effect of treatment on mononuclear cell migration in cervical cancer patients.
OBJECTIVE
Our aim was to evaluate the effect of treatment on the in vitro migration of circulating mononuclear cells in cervical cancer patients at different stages.


METHODS
We prospectively investigated 24 patients with cervical neoplasia, without prior treatment, submitted to surgery or chemotherapy as therapeutic conduct. Controls were healthy volunteer women (n = 23). Mononuclear cells were isolated from peripheral venous blood before and after treatment, and their migration capacity was evaluated in a microchemotaxis chamber assay towards the chemotactic stimuli fMLP, MCP-1 and RANTES, compared to basal migration. Serum levels of nitric oxide metabolites were assayed by the Griess reaction.


RESULTS
Increased mononuclear cell migration in response to the chemotactic stimuli, compared to basal migration, was observed in controls and patients, without differences between them. After treatment (n = 14), mononuclear cell migration in response to MCP-1 and RANTES was increased compared to pre-treatment. Serum levels of nitric oxide metabolites were more elevated in patients (n = 19) than in controls (n = 17), but decreased after treatment (n = 15).


CONCLUSIONS
The results suggest that the production of soluble circulating factors by tumor cells could interfere with the functional activity of blood mononuclear cells.
Garcia
Cristiana Bernadelli
CB
Department of Biological Sciences, Federal University of Triângulo Mineiro, Uberaba, MG, Brazil.
Fernandes
Paulo Cesar Júnior
PC
Micheli
Douglas Côbo
DC
Pereira
Ana Helena Macedo
AH
Murta
Eddie Fernando Candido
EF
Tavares-Murta
Beatriz Martins
BM
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D016022:Case-Control Studies; D002465:Cell Movement / Q000187:drug effects; D018932:Chemokine CCL2 / Q000187:drug effects; D018946:Chemokine CCL5 / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D005260:Female; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects*; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood / Q000378:metabolism; D011446:Prospective Studies; D044042:Receptors, Formyl Peptide / Q000187:drug effects; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology* / Q000601:surgery / Q000628:therapy*
C111835:CCL2 protein, human; D018932:Chemokine CCL2; D018946:Chemokine CCL5; D044042:Receptors, Formyl Peptide; D009569:Nitric Oxide